サマリー

遺伝性血管性浮腫治療薬の世界市場 2023-2027
遺伝性血管性浮腫治療薬市場は、2022年から2027年にかけて1億6,738万米ドルの成長が予測され、予測期間中のCAGRは8.95%で加速すると予測されます。この調査レポートは、遺伝性血管性浮腫治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。遺伝性血管性浮腫の有病率の増加、診断技術の進歩、医療インフラの成長などが市場を牽引しています。
Technavio社の遺伝性血管性浮腫治療薬市場は以下のように分類されます：
エンドユーザー別
- 病院薬局
- 小売薬局
- 電子商取引
製品別
- C1-エステラーゼ阻害剤
- ブラジキニンB2受容体拮抗薬
- カリクレイン阻害剤
- その他
地域別
- 北米
- 欧州
- アジア
- その他の地域（ROW）
本調査では、今後数年間の遺伝性血管性浮腫治療薬市場の成長を促進する主な理由の一つとして、個別化医療に対する需要の高まりを挙げています。また、モノクローナル抗体や遺伝子治療などの革新的で効果的な治療法の開発、希少疾病用医薬品開発のためのR&Dや資金調達の増加は、市場の大きな需要につながるでしょう。
本レポートでは、遺伝性血管性浮腫治療薬市場について、以下の分野をカバーしています：
- 遺伝性血管性浮腫治療薬市場のサイジング
- 遺伝性血管性浮腫治療薬市場予測
- 遺伝性血管性浮腫治療薬市場の産業分析
強固なベンダー分析は、クライアントが市場での地位を向上できるように設計されており、これに沿って、本レポートでは、Adverum Biotechnologies Inc、アチューン・ファーマシューティカルズ・インク、バイオクリスト・ファーマシューティカルズ・インク、バイオマリン・ファーマシューティカルズ・インク、CENTOGENE NV、Cipla Ltd.、CSL Ltd.、Diapharma Group Inc.、Intellia Therapeutics Inc.、Ionis Pharmaceuticals Inc.、KalVista Pharmaceuticals Inc.、Pharming Group NV、Pharvaris NV、サノフィ、武田薬品工業などです。また、遺伝性血管腫の治療薬も開発されている。また、遺伝性血管性浮腫治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/hereditary-angioedema-therapeutics-market-analysis をご覧ください。
当出版社では、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細なイメージを提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

ページTOPに戻る

目次

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by End-user
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global hereditary angioedema therapeutics market 2017 - 2021
o Exhibit 18: Historic Market Size - Data Table on global hereditary angioedema therapeutics market 2017 - 2021 ($ million)
o 4.2 End-User Segment Analysis 2017 - 2021
o Exhibit 19: Historic Market Size - End-User Segment 2017 - 2021 ($ million)
o 4.3 Product Segment Analysis 2017 - 2021
o Exhibit 20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 - 2021
o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
o 4.5 Country Segment Analysis 2017 - 2021
o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
• 6 Market Segmentation by End-user
o 6.1 Market segments
o Exhibit 30: Chart on End-user - Market share 2022-2027 (%)
o Exhibit 31: Data Table on End-user - Market share 2022-2027 (%)
o 6.2 Comparison by End-user
o Exhibit 32: Chart on Comparison by End-user
o Exhibit 33: Data Table on Comparison by End-user
o 6.3 Hospital pharmacies - Market size and forecast 2022-2027
o Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
o 6.4 Retail pharmacies - Market size and forecast 2022-2027
o Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
o 6.5 E-commerce - Market size and forecast 2022-2027
o Exhibit 42: Chart on E-commerce - Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on E-commerce - Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on E-commerce - Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on E-commerce - Year-over-year growth 2022-2027 (%)
o 6.6 Market opportunity by End-user
o Exhibit 46: Market opportunity by End-user ($ million)
o Exhibit 47: Data Table on Market opportunity by End-user ($ million)
• 7 Market Segmentation by Product
o 7.1 Market segments
o Exhibit 48: Chart on Product - Market share 2022-2027 (%)
o Exhibit 49: Data Table on Product - Market share 2022-2027 (%)
o 7.2 Comparison by Product
o Exhibit 50: Chart on Comparison by Product
o Exhibit 51: Data Table on Comparison by Product
o 7.3 C1-esterase inhibitor - Market size and forecast 2022-2027
o Exhibit 52: Chart on C1-esterase inhibitor - Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on C1-esterase inhibitor - Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on C1-esterase inhibitor - Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on C1-esterase inhibitor - Year-over-year growth 2022-2027 (%)
o 7.4 Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027
o Exhibit 56: Chart on Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Bradykinin B2 receptor antagonist - Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Bradykinin B2 receptor antagonist - Year-over-year growth 2022-2027 (%)
o 7.5 Kallikrein inhibitor - Market size and forecast 2022-2027
o Exhibit 60: Chart on Kallikrein inhibitor - Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Kallikrein inhibitor - Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Kallikrein inhibitor - Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Kallikrein inhibitor - Year-over-year growth 2022-2027 (%)
o 7.6 Others - Market size and forecast 2022-2027
o Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%)
o Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Product
o Exhibit 68: Market opportunity by Product ($ million)
o Exhibit 69: Data Table on Market opportunity by Product ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 71: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 73: Chart on Geographic comparison
o Exhibit 74: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2022-2027
o Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
o 9.4 Europe - Market size and forecast 2022-2027
o Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
o 9.5 Asia - Market size and forecast 2022-2027
o Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
o Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
o 9.7 US - Market size and forecast 2022-2027
o Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
o 9.8 China - Market size and forecast 2022-2027
o Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
o 9.9 Germany - Market size and forecast 2022-2027
o Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
o 9.10 Canada - Market size and forecast 2022-2027
o Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
o 9.11 India - Market size and forecast 2022-2027
o Exhibit 107: Chart on India - Market size and forecast 2022-2027 ($ million)
o Exhibit 108: Data Table on India - Market size and forecast 2022-2027 ($ million)
o Exhibit 109: Chart on India - Year-over-year growth 2022-2027 (%)
o Exhibit 110: Data Table on India - Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 111: Market opportunity By Geographical Landscape ($ million)
o Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 113: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 115: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 116: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 117: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 118: Matrix on vendor position and classification
o 12.3 Adverum Biotechnologies Inc.
o Exhibit 119: Adverum Biotechnologies Inc. - Overview
o Exhibit 120: Adverum Biotechnologies Inc. - Product / Service
o Exhibit 121: Adverum Biotechnologies Inc. - Key offerings
o 12.4 Arrowhead Pharmaceuticals Inc.
o Exhibit 122: Arrowhead Pharmaceuticals Inc. - Overview
o Exhibit 123: Arrowhead Pharmaceuticals Inc. - Business segments
o Exhibit 124: Arrowhead Pharmaceuticals Inc. - Key offerings
o Exhibit 125: Arrowhead Pharmaceuticals Inc. - Segment focus
o 12.5 Attune Pharmaceuticals Inc.
o Exhibit 126: Attune Pharmaceuticals Inc. - Overview
o Exhibit 127: Attune Pharmaceuticals Inc. - Product / Service
o Exhibit 128: Attune Pharmaceuticals Inc. - Key offerings
o 12.6 BioCryst Pharmaceuticals Inc.
o Exhibit 129: BioCryst Pharmaceuticals Inc. - Overview
o Exhibit 130: BioCryst Pharmaceuticals Inc. - Product / Service
o Exhibit 131: BioCryst Pharmaceuticals Inc. - Key offerings
o 12.7 BioMarin Pharmaceutical Inc.
o Exhibit 132: BioMarin Pharmaceutical Inc. - Overview
o Exhibit 133: BioMarin Pharmaceutical Inc. - Product / Service
o Exhibit 134: BioMarin Pharmaceutical Inc. - Key offerings
o 12.8 CENTOGENE NV
o Exhibit 135: CENTOGENE NV - Overview
o Exhibit 136: CENTOGENE NV - Product / Service
o Exhibit 137: CENTOGENE NV - Key offerings
o 12.9 Cipla Ltd.
o Exhibit 138: Cipla Ltd. - Overview
o Exhibit 139: Cipla Ltd. - Business segments
o Exhibit 140: Cipla Ltd. - Key news
o Exhibit 141: Cipla Ltd. - Key offerings
o Exhibit 142: Cipla Ltd. - Segment focus
o 12.10 CSL Ltd.
o Exhibit 143: CSL Ltd. - Overview
o Exhibit 144: CSL Ltd. - Business segments
o Exhibit 145: CSL Ltd. - Key news
o Exhibit 146: CSL Ltd. - Key offerings
o Exhibit 147: CSL Ltd. - Segment focus
o 12.11 Intellia Therapeutics Inc.
o Exhibit 148: Intellia Therapeutics Inc. - Overview
o Exhibit 149: Intellia Therapeutics Inc. - Business segments
o Exhibit 150: Intellia Therapeutics Inc. - Key offerings
o Exhibit 151: Intellia Therapeutics Inc. - Segment focus
o 12.12 Ionis Pharmaceuticals Inc.
o Exhibit 152: Ionis Pharmaceuticals Inc. - Overview
o Exhibit 153: Ionis Pharmaceuticals Inc. - Business segments
o Exhibit 154: Ionis Pharmaceuticals Inc. - Key news
o Exhibit 155: Ionis Pharmaceuticals Inc. - Key offerings
o Exhibit 156: Ionis Pharmaceuticals Inc. - Segment focus
o 12.13 KalVista Pharmaceuticals Inc.
o Exhibit 157: KalVista Pharmaceuticals Inc. - Overview
o Exhibit 158: KalVista Pharmaceuticals Inc. - Product / Service
o Exhibit 159: KalVista Pharmaceuticals Inc. - Key offerings
o 12.14 Pharming Group NV
o Exhibit 160: Pharming Group NV - Overview
o Exhibit 161: Pharming Group NV - Business segments
o Exhibit 162: Pharming Group NV - Key offerings
o Exhibit 163: Pharming Group NV - Segment focus
o 12.15 Pharvaris NV
o Exhibit 164: Pharvaris NV - Overview
o Exhibit 165: Pharvaris NV - Product / Service
o Exhibit 166: Pharvaris NV - Key offerings
o 12.16 Sanofi
o Exhibit 167: Sanofi - Overview
o Exhibit 168: Sanofi - Business segments
o Exhibit 169: Sanofi - Key news
o Exhibit 170: Sanofi - Key offerings
o Exhibit 171: Sanofi - Segment focus
o 12.17 Takeda Pharmaceutical Co. Ltd.
o Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
o Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
o Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
o Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 176: Inclusions checklist
o Exhibit 177: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 178: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 179: Research methodology
o Exhibit 180: Validation techniques employed for market sizing
o Exhibit 181: Information sources
o 13.5 List of abbreviations
o Exhibit 182: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by End-user
Exhibits6: Executive Summary - Chart on Market Segmentation by Product
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size - Data Table on global hereditary angioedema therapeutics market 2017 - 2021 ($ million)
Exhibits19: Historic Market Size - End-User Segment 2017 - 2021 ($ million)
Exhibits20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits23: Five forces analysis - Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition - Five forces 2022 and 2027
Exhibits30: Chart on End-user - Market share 2022-2027 (%)
Exhibits31: Data Table on End-user - Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by End-user
Exhibits33: Data Table on Comparison by End-user
Exhibits34: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on E-commerce - Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on E-commerce - Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on E-commerce - Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on E-commerce - Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by End-user ($ million)
Exhibits47: Data Table on Market opportunity by End-user ($ million)
Exhibits48: Chart on Product - Market share 2022-2027 (%)
Exhibits49: Data Table on Product - Market share 2022-2027 (%)
Exhibits50: Chart on Comparison by Product
Exhibits51: Data Table on Comparison by Product
Exhibits52: Chart on C1-esterase inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on C1-esterase inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on C1-esterase inhibitor - Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on C1-esterase inhibitor - Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Bradykinin B2 receptor antagonist - Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Bradykinin B2 receptor antagonist - Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Kallikrein inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Kallikrein inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Kallikrein inhibitor - Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Kallikrein inhibitor - Year-over-year growth 2022-2027 (%)
Exhibits64: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibits65: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibits66: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibits67: Data Table on Others - Year-over-year growth 2022-2027 (%)
Exhibits68: Market opportunity by Product ($ million)
Exhibits69: Data Table on Market opportunity by Product ($ million)
Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits71: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits73: Chart on Geographic comparison
Exhibits74: Data Table on Geographic comparison
Exhibits75: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits107: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibits108: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibits109: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibits110: Data Table on India - Year-over-year growth 2022-2027 (%)
Exhibits111: Market opportunity By Geographical Landscape ($ million)
Exhibits112: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits113: Impact of drivers and challenges in 2022 and 2027
Exhibits114: Overview on Criticality of inputs and Factors of differentiation
Exhibits115: Overview on factors of disruption
Exhibits116: Impact of key risks on business
Exhibits117: Vendors covered
Exhibits118: Matrix on vendor position and classification
Exhibits119: Adverum Biotechnologies Inc. - Overview
Exhibits120: Adverum Biotechnologies Inc. - Product / Service
Exhibits121: Adverum Biotechnologies Inc. - Key offerings
Exhibits122: Arrowhead Pharmaceuticals Inc. - Overview
Exhibits123: Arrowhead Pharmaceuticals Inc. - Business segments
Exhibits124: Arrowhead Pharmaceuticals Inc. - Key offerings
Exhibits125: Arrowhead Pharmaceuticals Inc. - Segment focus
Exhibits126: Attune Pharmaceuticals Inc. - Overview
Exhibits127: Attune Pharmaceuticals Inc. - Product / Service
Exhibits128: Attune Pharmaceuticals Inc. - Key offerings
Exhibits129: BioCryst Pharmaceuticals Inc. - Overview
Exhibits130: BioCryst Pharmaceuticals Inc. - Product / Service
Exhibits131: BioCryst Pharmaceuticals Inc. - Key offerings
Exhibits132: BioMarin Pharmaceutical Inc. - Overview
Exhibits133: BioMarin Pharmaceutical Inc. - Product / Service
Exhibits134: BioMarin Pharmaceutical Inc. - Key offerings
Exhibits135: CENTOGENE NV - Overview
Exhibits136: CENTOGENE NV - Product / Service
Exhibits137: CENTOGENE NV - Key offerings
Exhibits138: Cipla Ltd. - Overview
Exhibits139: Cipla Ltd. - Business segments
Exhibits140: Cipla Ltd. - Key news
Exhibits141: Cipla Ltd. - Key offerings
Exhibits142: Cipla Ltd. - Segment focus
Exhibits143: CSL Ltd. - Overview
Exhibits144: CSL Ltd. - Business segments
Exhibits145: CSL Ltd. - Key news
Exhibits146: CSL Ltd. - Key offerings
Exhibits147: CSL Ltd. - Segment focus
Exhibits148: Intellia Therapeutics Inc. - Overview
Exhibits149: Intellia Therapeutics Inc. - Business segments
Exhibits150: Intellia Therapeutics Inc. - Key offerings
Exhibits151: Intellia Therapeutics Inc. - Segment focus
Exhibits152: Ionis Pharmaceuticals Inc. - Overview
Exhibits153: Ionis Pharmaceuticals Inc. - Business segments
Exhibits154: Ionis Pharmaceuticals Inc. - Key news
Exhibits155: Ionis Pharmaceuticals Inc. - Key offerings
Exhibits156: Ionis Pharmaceuticals Inc. - Segment focus
Exhibits157: KalVista Pharmaceuticals Inc. - Overview
Exhibits158: KalVista Pharmaceuticals Inc. - Product / Service
Exhibits159: KalVista Pharmaceuticals Inc. - Key offerings
Exhibits160: Pharming Group NV - Overview
Exhibits161: Pharming Group NV - Business segments
Exhibits162: Pharming Group NV - Key offerings
Exhibits163: Pharming Group NV - Segment focus
Exhibits164: Pharvaris NV - Overview
Exhibits165: Pharvaris NV - Product / Service
Exhibits166: Pharvaris NV - Key offerings
Exhibits167: Sanofi - Overview
Exhibits168: Sanofi - Business segments
Exhibits169: Sanofi - Key news
Exhibits170: Sanofi - Key offerings
Exhibits171: Sanofi - Segment focus
Exhibits172: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibits173: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibits174: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibits175: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibits176: Inclusions checklist
Exhibits177: Exclusions checklist
Exhibits178: Currency conversion rates for US$
Exhibits179: Research methodology
Exhibits180: Validation techniques employed for market sizing
Exhibits181: Information sources
Exhibits182: List of abbreviations